<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of new drugs to treat vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> and other conditions in which <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> is due at least in part to vascular pathology will require future interaction among academic, industry, and government regulatory clinicians and scientists </plain></SENT>
<SENT sid="1" pm="."><plain>This article offers the author's perspective on the positive involvement of the Food and Drug Administration in development of conceptual frameworks and practical approaches to treatment of conditions characterized by vascular burden of the brain </plain></SENT>
</text></document>